Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) from a hold rating to a sell rating in a research note released on Monday.

A number of other brokerages have also weighed in on INO. Royal Bank of Canada decreased their target price on Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating for the company in a research report on Wednesday, March 19th. HC Wainwright reissued a "neutral" rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $9.75.

Inovio Pharmaceuticals Price Performance

Shares of Inovio Pharmaceuticals stock traded up $0.07 on Monday, reaching $1.95. The company had a trading volume of 411,080 shares, compared to its average volume of 590,841. The firm has a market cap of $71.51 million, a price-to-earnings ratio of -0.49 and a beta of 1.40. The firm's 50-day moving average price is $1.80 and its two-hundred day moving average price is $2.53. Inovio Pharmaceuticals has a 1 year low of $1.42 and a 1 year high of $13.44.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.23. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.01 million. As a group, analysts anticipate that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Nomura Holdings Inc. acquired a new position in shares of Inovio Pharmaceuticals in the 1st quarter valued at about $28,000. Alpine Global Management LLC acquired a new position in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $31,000. Freedom Investment Management Inc. acquired a new position in shares of Inovio Pharmaceuticals during the first quarter valued at approximately $31,000. Bank of Montreal Can acquired a new position in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $43,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $44,000. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.